Literature DB >> 1624675

Plasma growth hormone (GH) responses to corticotropin-releasing hormone in patients with acromegaly--the effect of dexamethasone pretreatment and the comparison with GH responses to thyrotropin-releasing hormone, gonadotropin-releasing hormone and GH-releasing hormone.

A Utsumi1, K Hanew, A Sugawara, Y Shimizu, O Murakami, H Ikeda, K Yoshinaga.   

Abstract

It has been reported that paradoxical GH responses to corticotropin-releasing hormone (CRH) occur in only few patients with acromegaly. However, we have observed such responses in 7 of 14 active acromegalic patients. Therefore, we have studied the GH responses to thyrotropin-releasing hormone (TRH) (500 micrograms, iv), gonadotropin-releasing hormone (LHRH) (100 micrograms, iv) and GH-releasing hormone (GHRH) (100 micrograms, iv) in these patients to examine the relationships between the GH responses to CRH and the responses to these hypothalamic hormones. Further, these patients received human CRH (1-41) NH2 (100 micrograms, iv) with or without dexamethasone (Dex) pretreatment (1 mg/100 ml saline, iv, from -30 to +30 min) to study the mechanism of CRH-induced GH secretion, and a perifusion experiment was performed using adenoma tissue obtained at surgery from one patient (10(-7) M CRH and TRH were added) to elucidate whether CRH acts directly at the pituitary level. Aberrant GH responses induced by CRH were found in 7 of 14 (50%) acromegalic patients (TRH responders: 10/13, 77%; LHRH responders: 2/9, 22%; GHRH responders: 10/12, 83%). In these patients, percent GH increment induced by CRH ranged from 81 to 144% (Mean +/- SE, 118 +/- 8%), and the GH peak (19 +/- 3 min) appeared as early as after TRH (23 +/- 4 min, N = 10).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1624675     DOI: 10.1007/BF03348697

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  12 in total

1.  The spectrum of GH responses to GHRH and somatostatin in patients with acromegaly.

Authors:  K Hanew; S Sato; M Goh; A Sasaki; Y Shimizu; A Sugawara; T Ohtsuka; K Yoshinaga
Journal:  Tohoku J Exp Med       Date:  1988-07       Impact factor: 1.848

2.  The spectrum of pituitary growth hormone responses to pharmacological stimuli in acromegaly.

Authors:  K Hanew; M Kokubun; A Sasaki; T Mouri; K Yoshinaga
Journal:  J Clin Endocrinol Metab       Date:  1980-08       Impact factor: 5.958

3.  Increase of serum growth hormone concentration following thyrotropin-releasing hormone injection in patients with acromegaly or gigantism.

Authors:  M Irie; T Tsushima
Journal:  J Clin Endocrinol Metab       Date:  1972-07       Impact factor: 5.958

4.  Human pancreatic growth hormone-releasing factor-44 differentially stimulates release of stored and newly synthesized rat growth hormone in vitro.

Authors:  M E Stachura; J M Tyler; P K Farmer
Journal:  Endocrinology       Date:  1985-02       Impact factor: 4.736

5.  Paradoxical responsiveness of growth hormone to corticotropin-releasing factor in acromegaly.

Authors:  G F Pieters; A R Hermus; A G Smals; P W Kloppenborg
Journal:  J Clin Endocrinol Metab       Date:  1984-03       Impact factor: 5.958

6.  Effect of synthetic ovine corticotropin-releasing factor on growth hormone secretion in patients with acromegaly.

Authors:  K Tanaka; T Watabe; H Yoshida; N Shimizu
Journal:  Endocrinol Jpn       Date:  1984-06

7.  Failure of growth hormone-suppressing agents to affect TSH-releasing hormone- and LH-releasing hormone-induced growth hormone release in acromegaly.

Authors:  K Nakagawa; T Obara
Journal:  J Clin Endocrinol Metab       Date:  1977-01       Impact factor: 5.958

8.  Effects of ovine corticotrophin-releasing factor and hydrocortisone on growth hormone secretion by pituitary adenoma cells of acromegaly in culture.

Authors:  M Ishibashi; T Hara; Y Tagusagawa; T Fukushima; H Numata; T Hori; T Yamaji
Journal:  Acta Endocrinol (Copenh)       Date:  1984-08

9.  Corticotrophin releasing factor: responses in normal subjects and patients with disorders of the hypothalamus and pituitary.

Authors:  N Lytras; A Grossman; L Perry; S Tomlin; J A Wass; D H Coy; A V Schally; L H Rees; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1984-01       Impact factor: 3.478

10.  Effect of dexamethasone on growth hormone (GH) response to growth hormone releasing hormone in acromegaly.

Authors:  K Nakagawa; K Akikawa; M Matsubara; M Kubo
Journal:  J Clin Endocrinol Metab       Date:  1985-02       Impact factor: 5.958

View more
  1 in total

Review 1.  Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly.

Authors:  Laure Cazabat; Jean-Claude Souberbielle; Philippe Chanson
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.